^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Juvenile Myelomonocytic Leukemia |
| Drug: | azacitidine (DNMT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
05/20/2022
Excerpt:
VIDAZA is a nucleoside metabolic inhibitor indicated for the treatment of...Pediatric patients aged 1 month and older with newly diagnosed Juvenile Myelomonocytic Leukemia (JMML).
